Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of Zastaprazan in Healthy Men
NCT03383042Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Dec 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zastaprazan in gastroesophageal reflux disease (GERD) (9 cohorts), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Curve to Last Measurable Concentration at 48 hours and 9 more. Started Dec 2017; status: completed.
02
Drugs
zastaprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03383042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03383042.